Skip to main content

Table 2 Mixed effects linear regression model fitting assessment of association of chemotherapy type with chromosome-specific telomere length

From: Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study

Chromosome arm Least square mean p value  
TAC1 TC TCH FDR
1p 4.346 (0.251)* 2.944 (0.451) 2.813 (0.501) 0.004 0.048
1q 5.642 (0.314) 4.016 (0.564) 4.433 (0.626) 0.028 0.056
2p 5.602 (0.315) 3.929 (0.565) 4.174 (0.628) 0.017 0.048
2q 4.247 (0.263) 3.125 (0.473) 3.486 (0.526) 0.094 0.101
3p 6.252 (0.319) 4.671 (0.574) 5.508 (0.637) 0.059 0.075
3q 5.488 (0.317) 3.853 (0.570) 4.051 (0.634) 0.020 0.048
4p 4.475 (0.280) 3.671 (0.502) 3.436 (0.558) 0.157 0.160
4q 5.876 (0.326) 4.425 (0.586) 4.689 (0.651) 0.059 0.075
5p 5.451 (0.295) 3.696 (0.531) 4.376 (0.589) 0.014 0.048
5q 4.590 (0.309) 3.682 (0.556) 3.714 (0.618) 0.064 0.080
6p 5.698 (0.298) 4.028 (0.536) 4.417 (0.596) 0.015 0.048
6q 5.383 (0.312) 3.835 (0.561) 4.279 (0.623) 0.039 0.064
7p 4.598 (0.269) 3.465 (0.484) 3.383 (0.538) 0.043 0.066
7q 5.335 (0.305) 3.673 (0.549) 4.163 (0.609) 0.022 0.050
8p 5.453 (0.288) 3.821 (0.518) 4.301 (0.575) 0.016 0.048
8q 4.685 (0.312) 3.252 (0.561) 3.593 (0.623) 0.056 0.075
9p 5.664 (0.314) 4.201 (0.564) 4.304 (0.627) 0.034 0.058
9q 4.037 (0.259) 2.581 (0.465) 2.821 (0.517) 0.012 0.048
10p 5.729 (0.313) 4.114 (0.562) 4.107 (0.624) 0.013 0.048
10q 4.821 (0.299) 3.726 (0.537) 3.531 (0.597) 0.070 0.083
11p 4.791 (0.292) 3.639 (0.524) 3.758 (0.582) 0.090 0.099
11q 5.413 (0.327) 4.152 (0.587) 3.837 (0.653) 0.045 0.067
12p 4.890 (0.287) 3.289 (0.515) 3.918 (0.572) 0.023 0.050
12q 4.838 (0.289) 3.674 (0.520) 3.791 (0.578) 0.083 0.093
13p 5.093 (0.289) 3.422 (0.519) 4.096 (0.576) 0.018 0.048
13q 5.599 (0.323) 4.146 (0.580) 4.111 (0.645) 0.033 0.058
14p 5.221 (0.314) 3.349 (0.565) 3.864 (0.628) 0.010 0.048
14q 5.000 (0.312) 3.487 (0.561) 3.856 (0.623) 0.041 0.065
15p 4.885 (0.285) 3.131 (0.512) 3.896 (0.569) 0.012 0.048
15q 5.535 (0.318) 3.823 (0.571) 4.112 (0.634) 0.017 0.048
16p 4.064 (0.237) 2.993 (0.426) 3.137 (0.473) 0.049 0.070
16q 4.614 (0.281) 3.126 (0.504) 3.398 (0.560) 0.020 0.048
17p 4.282 (0.250) 3.083 (0.449) 4.464 (0.499) 0.051 0.071
17q 4.265 (0.276) 3.126 (0.496) 3.507 (0.551) 0.110 0.115
18p 5.224 (0.322) 4.218 (0.578) 4.404 (0.643) 0.238 0.238
18q 5.556 (0.292) 4.058 (0.526) 4.310 (0.584) 0.024 0.050
19p 4.281 (0.248) 2.280 (0.445) 3.185 (0.495) 0.010 0.048
19q 4.852 (0.261) 3.232 (0.469) 3.786 (0.522) 0.009 0.048
20p 5.054 (0.300) 3.684 (0.539) 4.122 (0.599) 0.067 0.081
20q 4.430 (0.262) 2.917 (0.470) 3.414 (0.522) 0.015 0.048
21p 5.356 (0.278) 3.474 (0.500) 4.242 (0.555) 0.005 0.048
21q 4.700 (0.257) 3.121 (0.462) 3.267 (0.513) 0.004 0.048
22p 5.068 (0.282) 3.438 (0.506) 3.995 (0.562) 0.016 0.048
22q 4.269 (0.264) 3.086 (0.475) 3.028 (0.527) 0.031 0.058
Xp 5.518 (0.322) 4.320 (0.579) 4.190 (0.643) 0.077 0.089
Xq 5.237 (0.316) 3.834 (0.567) 3.756 (0.630) 0.032 0.058
  1. *The standard error is shown in parenthesis; bold rows indicate values showing statistical significance using an FDR threshold
  2. 1TAC = sequential administration of docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide (Cytoxan); TC = docetaxel (Taxotere) and cyclophosphamide (Cytoxan); TCH = docetaxel (Taxotere), Carboplatin (Paraplatin), and trastuzumab (Herceptin)